Short Interest in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) Increases By 190.9%

Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) was the recipient of a significant increase in short interest in the month of July. As of July 31st, there was short interest totaling 135,284 shares, an increase of 190.9% from the July 15th total of 46,508 shares. Based on an average daily volume of 95,778 shares, the days-to-cover ratio is presently 1.4 days.

Institutional Trading of Drugs Made In America Acquisition II

A number of institutional investors have recently bought and sold shares of DMII. Deltec Asset Management LLC bought a new position in shares of Drugs Made In America Acquisition II during the fourth quarter worth approximately $495,000. Wolverine Asset Management LLC acquired a new stake in Drugs Made In America Acquisition II during the fourth quarter worth approximately $10,521,000. ABC Arbitrage SA bought a new position in Drugs Made In America Acquisition II during the 4th quarter worth $396,000. Wealthspring Capital LLC acquired a new position in Drugs Made In America Acquisition II in the 4th quarter valued at $4,049,000. Finally, HighTower Advisors LLC acquired a new position in Drugs Made In America Acquisition II in the 4th quarter valued at $7,817,000.

Drugs Made In America Acquisition II Stock Performance

Shares of Drugs Made In America Acquisition II stock traded down $0.01 during trading on Thursday, reaching $10.12. The company’s stock had a trading volume of 5,125 shares, compared to its average volume of 114,100. The firm’s 50-day moving average price is $10.09. Drugs Made In America Acquisition II has a 52 week low of $9.86 and a 52 week high of $10.20.

Wall Street Analysts Forecast Growth

DMII has been the subject of a number of research reports. Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Wall Street Zen raised shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Drugs Made In America Acquisition II currently has an average rating of “Sell”.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.